Keros Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KROS research report →
Range $18 – $23
Price Chart
About the company
Keros Therapeutics, Inc. , a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis.
- CEO
- Jasbir S. Seehra
- IPO
- 2020
- Employees
- 92
- HQ
- Lexington, MA, US
Get TickerSpark's AI analysis on KROS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $350.38M
- P/E
- -2.96
- PEG
- 0.00
- P/S
- 23.34
- P/B
- 0.83
- EV/EBITDA
- -1.28
- Div Yield
- 0.00%
- Gross Margin
- 94.68%
- Op Margin
- -675.82%
- Net Margin
- -553.88%
- ROE
- -21.40%
- ROIC
- -35.25%
Latest fiscal year · YoY change
- Revenue
- $244.06M+6775.0%
- Gross Profit
- $242.55M+6732.5%
- Op Income
- $70.62M
- Net Income
- $87.01M+146.4%
- EPS
- $2.34+146.8%
- OCF Growth
- +166.8%
- FCF Growth
- +165.1%
- 52W High
- $22.55
- 52W Low
- $9.69
- 50D MA
- $10.65
- 200D MA
- $13.95
- Beta
- 1.01
- RSI (14)
- 54
- Avg Volume
- 255.59K
No earnings-call transcripts are available for KROS yet.
- Free Float
- 92.3%
- Shares Outstanding
- 32.00M
- Float Shares
- 29.53M
of shares held by institutions
172 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.53M | ▼ 1.19M |
| Two Sigma Advisers, LP | 171.80K | ▲ 117.60K |
| Cubist Systematic Strategies, LLC | 121.53K | ▲ 121.53K |
| Nebula Research & Development LLC | 90.41K | ▼ 25.01K |
| Quest Partners LLC | 32.09K | ▲ 16.84K |
| Advantage Alpha Capital Partners LP | 18.06K | ▲ 18.06K |
| Cwm, LLC | 8.62K | ▲ 4.79K |
| California State Teachers Retirement System | 1.58K | ▼ 218 |
| Point72 Asia (Singapore) Pte. Ltd. | 1.24K | ▲ 1.24K |
| Point72 (Difc) Ltd | 964 | ▲ 964 |
| Red Tortoise LLC | 56 | 0 |
| Parkside Financial Bank & Trust | 55 | 0 |
Held by 135 ETFs
Biggest fund positions in KROS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 18, 26 | Tanini Annita | sell | 1,224 |
| Aug 18, 26 | Lerner Lorena Raquel | sell | 3,568 |
| Aug 18, 26 | Cho Esther | sell | 4,485 |
| Aug 18, 26 | Newton Charles W. | sell | 551 |
| Aug 17, 26 | BIENAIME JEAN JACQUES | buy | 1,000 |
| Aug 4, 26 | Tanini Annita | other | 0 |
| Aug 4, 26 | Tanini Annita | other | 7,500 |
| Aug 4, 26 | Tanini Annita | other | 25,000 |
| Aug 4, 26 | Tanini Annita | other | 6,000 |
| Aug 4, 26 | Tanini Annita | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KROS coverage
Recent articles, reports, and earnings notes.
No research on KROS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KROS report →Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP
defenseworld.net · Aug 13
Keros Therapeutics, Inc. $KROS Shares Acquired by Empowered Funds LLC
defenseworld.net · Aug 8
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
zacks.com · Aug 4
Keros Therapeutics Reports Second Quarter 2026 Financial Results
globenewswire.com · Aug 3
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
globenewswire.com · Jul 30
New Strong Sell Stocks for July 30th
zacks.com · Jul 30
Keros Therapeutics Appoints Anne Prener to its Board of Directors
globenewswire.com · Jun 25
Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com · Jun 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.